Peripheral Neuropathy Market By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

General population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the U.K. alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030. Anticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously report cost-benefit to insurers and regulatory bodies. In terms of market competition, the existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion

The report titled “Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2017 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).

Geographically, the global peripheral neuropathy market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peripheral neuropathy market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peripheral neuropathy market. This report concludes with company profiles section that highlights major information about the key players engaged in global peripheral neuropathy market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Peripheral Neuropathy Market

Choose License Type
Published Date:  May 2017
Category:  Pharmaceuticals
Report ID:   58475
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Connect With Us
24/7 Research Support